Sponsor or institution
Clinical trials and research at Changchun GeneScience Pharmaceutical Co., Ltd.
As of November 12, 2026, Find a Trial lists 28 clinical trials run by Changchun GeneScience Pharmaceutical Co., Ltd. that are recruiting, at sites in 2 countries (most in China (28), United States (1)). By phase: Phase 1 (14), Phase 2 (5), Phase 4 (2), Phase 3 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 28Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| RhGH injections for adults with short bowel syndrome on PN | Phase 4 | Xiamen, Fujian and 1 other locations | Recruiting | Jul 8, 2026 |
| GenSci144 tablets early-dose study for phenylketonuria treatment | Phase 1 | Jinan, Shandong | Recruiting | Jul 6, 2026 |
| GenSci142 as a vaginal treatment for bacterial vaginosis | Phase 1 | Beijing, Beijing Municipality and 8 other locations | Recruiting | Jun 23, 2026 |
| Safety and efficacy of Corifollitropin Alfa N02 for older women undergoing IVF/ICSI | — | Beijing, Beijing Municipality | Recruiting | Apr 28, 2026 |
| GenSci048 vs placebo in active non-infectious uveitis | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | Apr 23, 2026 |
| GenSci161 safety and how the body handles it in healthy adults | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Mar 17, 2026 |
| GenSci120 in RA patients who did not respond to DMARDs | Phase 2 | Beijing, Beijing Municipality | Recruiting | Feb 20, 2026 |
| GenSci145: testing a new medicine alone or with a partner for PIK3CA-mutated solid tumors | Phase 1 | Beijing, Beijing Municipality | Recruiting | Feb 12, 2026 |
| Subcutaneous GenSci136 given to healthy adults to check safety and body behavior | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Jan 26, 2026 |
| GenSci098 for adults with Graves' disease | Phase 1 | Shenyang, Liaoning | Recruiting | Dec 16, 2025 |
All recruiting trials (28)
-
RhGH injections for adults with short bowel syndrome on PN
This study tests whether giving growth hormone injections helps adults with short bowel syndrome who rely on parenteral nutrition.
-
GenSci144 tablets early-dose study for phenylketonuria treatment
This early-phase trial tests a single dose of GenSci144 tablets in healthy adults to see if it is safe and tolerable, while also looking at how the body processes the drug.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
-
Safety and efficacy of Corifollitropin Alfa N02 for older women undergoing IVF/ICSI
This observational study tests whether Corifollitropin alfa N02 injections are safe and effective for women aged 36–40 undergoing IVF/ICSI with COS.
-
GenSci048 vs placebo in active non-infectious uveitis
This study tests whether GenSci048 can help people with active non-infectious uveitis compared with placebo.
-
GenSci161 safety and how the body handles it in healthy adults
This trial will test whether GenSci161 is safe, well tolerated, and how it's processed by the body in healthy adults aged 18 to 45.
-
GenSci120 in RA patients who did not respond to DMARDs
This study tests GenSci120 at different doses to see if it helps adults with moderately to severely active rheumatoid arthritis who haven’t had enough relief from at least one DMARD.
-
GenSci145: testing a new medicine alone or with a partner for PIK3CA-mutated solid tumors
This trial tests GenSci145 as a pill taken by adults with PIK3CA-mutated locally advanced or metastatic solid tumors, either alone or with another therapy, to see if it is safe and shows signs of helping tumors shrink or stay away.
-
Subcutaneous GenSci136 given to healthy adults to check safety and body behavior
This trial tests whether a single or repeated subcutaneous dose of GenSci136 is safe and how it behaves in the body of healthy adults aged 18–45.
-
GenSci098 for adults with Graves' disease
This phase 1 trial will test single increasing subcutaneous doses of GenSci098 to see if they are safe and well tolerated in adults with Graves' disease.
-
Oral GS3-007a for children with growth hormone deficiency
This study tests whether GS3-007a given as an oral suspension can help children with growth hormone deficiency, compared with placebo in Part 1 and with an approved treatment in Part 2.
-
PEG-rhGH versus hGH injections for short children born small for gestational age
This test will see if weekly PEG-rhGH injections or daily hGH injections help prepubertal children born small for gestational age grow taller.
-
GenSci143 for advanced solid tumors
This trial will test whether the experimental drug GenSci143 is safe and can shrink or slow tumors in adults with advanced solid cancers who have exhausted or cannot tolerate standard treatments.
-
GenSci140 for advanced solid tumors
This Phase 1 test will try GenSci140 to see if it is safe and shows early signs of benefit in adults with advanced solid tumors, including FRα-positive ovarian cancer.
-
Nanocrystalline megestrol acetate for cancer-related cachexia in routine care
This project tries nanocrystalline megestrol acetate to help adults with cancer-related cachexia who are starting this treatment in routine care.
-
GenSci139 for adults with advanced solid tumors
This study will try GenSci139 in adults with locally advanced or metastatic solid tumors to see if it is safe and can slow or shrink tumors.
-
Nanocrystalline megestrol acetate added to chemoradiotherapy for locally advanced non-small cell lung cancer
This trial will test whether adding nanocrystalline megestrol acetate to standard concurrent chemoradiotherapy helps improve appetite and body weight in adults with stage III non-small cell lung cancer.
-
Cabergoline versus bromocriptine for treating hyperprolactinemia in women
This trial tests whether cabergoline tablets work better and are as safe as bromocriptine tablets for women aged 18–45 with hyperprolactinemia.
-
Multiple subcutaneous injections of GenSci120 in healthy adults in China
This trial will test multiple subcutaneous doses of GenSci120 versus placebo in healthy adults to see if the drug is safe, well tolerated, and how it behaves in the body.
-
GenSci134 in healthy adults and adults with growth hormone deficiency
This Phase 1 trial will test single and multiple subcutaneous doses of GenSci134 in healthy adults and single doses in adults with growth hormone deficiency to check safety, tolerability, pharmacokinetics, pharmacodynamics, and immune response.
-
GenSci048 for moderate to severe endometriosis pain
This study will test if GenSci048 reduces moderate to severe endometriosis pain in premenopausal women.
-
Evaluating Nano-Crystalline Megestrol Acetate for Cachexia in Advanced Digestive Tumors
This study is testing if a new form of Megestrol Acetate can help adults with advanced digestive tumors gain weight and feel better while they are on cancer treatment.
-
First-in-human GenSci128 treatment for solid tumors with the TP53 Y220C mutation
This trial will test whether the oral drug GenSci128 is safe, well tolerated, and can help adults with advanced or metastatic solid tumors that have the TP53 Y220C mutation.
-
Using nano-crystalline megestrol to treat cancer-related fatigue in advanced gastric or colorectal cancer
This study is testing if a new form of megestrol can help people with advanced gastric or colorectal cancer feel less tired when combined with their usual treatment.
-
Investigating GenSci122 for advanced solid tumors
This study is testing a new medication called GenSci122 to see if it is safe and effective for people with advanced solid tumors.
-
Evaluating GenSci098 for treating active thyroid eye disease
This study is testing a new treatment called GenSci098 to see if it is safe and helpful for people with active thyroid eye disease linked to Graves' disease.
-
Evaluating Genakumab for Lung Disease Related to Connective Tissue Disorders
This study is testing whether an injection called Genakumab can help people with lung disease caused by connective tissue disorders like rheumatoid arthritis and systemic sclerosis feel better.
-
Evaluating GenaKumab for treating active systemic juvenile idiopathic arthritis
This study is testing a new medication called GenaKumab to see if it helps children and teens with active systemic juvenile idiopathic arthritis feel better and stay safe while using it.
Quick answers
How many clinical trials run by Changchun GeneScience Pharmaceutical Co., Ltd. are recruiting right now?
28, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (28 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 14, Phase 2: 5, Phase 4: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.